logo-loader

Silo Pharma CEO discusses latest license agreement with the University of Maryland

Published: 12:28 22 Feb 2021 EST

Silo Pharma, Inc (OTCQB:SILO) CEO Eric Weisblum talks to Proactive about the developmental stage biopharmaceutical company's latest license agreement with the University of Maryland to treat multiple sclerosis and other neuroinflammatory pathology.

Weisblum will be presenting at Proactive's One2One Investor Forum on February 23 at 1pm ET.

Proactive One2One Forum, Tuesday 02/23 13:00 EST

We are delighted to invite you to attend the next Proactive ONE2ONE Investor Forum which is taking place on Tuesday February 23rd from 1pm EST via our online interactive webinar conference Proactive continues to bring you the best investment opportunities safely to the comfort of your own...

on 23/2/21